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Original Article
Purpose: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among women in reproductive age. Conflicting results are 
reported in the studies examining insulin resistance in lean PCOS subjects. We aimed to observe the controversial presence of insulin resistance 
in lean PCOS subjects with the gold standard method and assess the impacts of family history of type 2 diabetes mellitus (T2DM) on insulin 
resistance in these patients.
Material and Method: Nineteen patients with PCOS and nine age-BMI matched control subjects were recruited into the study. Patients with PCOS 
were divided into two groups according to their FH of T2DM among their first degree relatives (FHneg vs FHpos). Insulin resistance was evaluated 
with homeostasis model assessment of insulin resistance (HOMA-IR) and hyperinsulinemic euglycemic clamp technique for all participants. 
Results: Mean M values were significantly higher in the control group when compared with PCOS patients (p=0.003). There was no statistically 
significant difference for HOMA-IR and M values when FHneg and FHpos patients were compared. Although HOMA-IR values were similar 
between all groups, M values were lower in FHneg and FHpos groups compared to the controls (p=0.02 and 0.004 respectively). 
Discussion: Lean PCOS patients have evident insulin resistance when compared to healthy subjects, and FH of T2DM seems to not affect insulin 
resistance. Even non-obese PCOS patients should be encouraged for healthy eating style and exercise to prevent the potential risks associated with 
insulin resistance. Furthermore these patients can see benefits from medical therapies which improve insulin sensitivity. Turk Jem 2015; 19: 55-59
Key words: Polycystic ovary syndrome, insulin resistance, diabetes mellitus 
Conflicts of Interest: The authors reported no conflict of interest related to this article.
Amaç: Polikistik over sendromu (PKOS) üreme çağındaki kadınlarda en sık görülen endokrin hastalıktır. Zayıf PKOS’lu olgularda insülin direncini 
araştıran çalışmalarda çelişkili sonuçlar bildirilmiştir. Çalışmamızda, zayıf PKOS hastalarında tartışmalı insülin direnci varlığını altın standart yöntem 
ile değerlendirmeyi ve bu hastalarda ailede tip 2 diabetes mellitus (T2DM) öyküsünün insülin direnci üzerine etkilerini araştırmayı amaçladık.
Gereç ve Yöntem: Çalışmaya 19 PKOS’lu hasta ve 9 yaş-VKİ benzer sağlıklı kontrol alındı. PKOS’lu hastalar birinci derece akrabalarında T2DM 
öyküsü varlığına göre iki gruba ayrıldı. Tüm katılanlarda insülin direnci “homeostasis model assessment of insulin resistance (HOMA-IR)” ve 
hiperinsülinemik öglisemik klemp tekniği ile ölçüldü.
Bulgular: Kontrol grubunda ortalama M değerleri PKOS’lu hastalara göre anlamlı derecede yüksekti (p=0,003). Ailesinde T2DM öyküsü olan ve 
olmayan PKOS’lu hastalar HOMA-IR ve M değerleri ile kıyaslandığında istatistiki anlamlı fark saptanmadı. Tüm gruplarda HOMA-IR değerleri 
benzer olmakla birlikte, T2DM aile öyküsü olmayan ve olan hastaların M değerleri konrol grubuna göre anlamlı düşüktü (sırasıyla; p=0,02 ve 
0,004).
Tartışma: Sağlıklı kişiler ile kıyaslandığında zayıf PKOS hastalarında artmış insülin direnci bulunmaktadır ve ailede T2DM öyküsü varlığı insülin 
direncini etkilemiyor gözükmektedir. Obez olmayan PKOS’lu hastalar bile insülin direnci ile ilişkili potansiyel risklerden korunmak için sağlıklı 
beslenme ve egzersiz alışkanlığının edinilmesi yönünden bilinçlendirilmelidir. Ayrıca bu hastalar medikal tedavi seçeneği olarak insülin 
duyarlılığını arttıran ilaçlardan fayda görebilir. Turk Jem 2015; 19: 55-59
Anahtar kelimeler: Polikistik over sendromu, insülin direnci, diabetes mellitus
Çıkar Çatışması: Yazarlar bu makale ile ilgili olarak herhangi bir çıkar çatışması bildirmemiştir.
Address for Correspondence: Emre Bozkırlı MD, Başkent University Faculty of Medicine, Department of Endocrinology and Metabolism, Adana, Turkey
Phone: +90 532 684 39 93  E-mail: emrebozk@yahoo.com  Received: 22/08/2014  Accepted: 26/12/2014
Emre Bozkırlı, Okan Bakıner, Eda Ertörer, İnan Anaforoğlu*, Neslihan Başçıl Tütüncü**, Nilgün Güvener Demirağ***
Başkent University Faculty of Medicine, Department of Endocrinology and Metabolism, Adana, Turkey
*Trabzon Numune Education and Research Hospital, Department of Endocrinology and Metabolism, Trabzon, Turkey
**Başkent University Faculty of Medicine, Department of Endocrinology and Metabolism, Ankara, Turkey
***Başkent University Faculty of Medicine, Department of Endocrinology and Metabolism, İstanbul, Turkey
Insulin Resistance in Non-Obese Polycystic Ovary Syndrome 
Subjects and Relation with Family History of Diabetes Mellitus
Obez Olmayan Polikistik Over Sendromlu Olgularda İnsülin Direnci ve 
Diabetes Mellitus Aile Öyküsü ile İlişkisi 
DOI: 10.4274/tjem.2761
Abs tract
Özet
55 
56 Turk Jem 2015; 19: 55-59
Bozkırlı et al.
Insulin Resistance in Lean PCOS Subjects
Introduction
Polycystic ovary syndrome (PCOS) is one of the most common 
endocrine disorders among premenopausal women, with a 
varying prevalence of 6.1-19.9% depending on the diagnostic 
criteria used (1). The characteristic features of the syndome are 
hyperandrogenism and chronic anovulation in the absence of 
specific diseases of the ovaries, adrenals and pituitary gland. In 
addition to fertility problems, patients are under risk for obesity, 
type 2 diabetes mellitus (T2DM), hypertension, dyslipidemia and 
cardiovascular diseases (2,3).
Besides the β-cell insulin secretory defects, insulin resistance (IR) 
and hyperinsulinemia play a key role in the pathogenesis of the 
disease (4). Most of the women with PCOS are insulin-resistant, 
and they have significantly increased risk for glucose metabolism 
disorders such as impaired glucose tolerance (IGT) and T2DM. It 
is well known that obese women with PCOS have evident IR in the 
base of excess fat tissue. However, conflicting results are reported 
in the studies examining IR in lean PCOS subjects (5,6).
A family history (FH) of T2DM is an evident increased risk for 
the development of T2DM in individuals without PCOS; but the 
question whether this is also acceptable in PCOS has been 
evaluated in relatively few studies of limited sample size (7,8,9,10). 
In a recent study; Lerchbaum et al. reported an independent 
association between FH of T2DM and central fat accumulation, 
obesity, prediabetes, metabolic syndrome, insulin resistance, 
low HDL and elevated blood pressure in 714 PCOS women (11). 
However, most of these studies including Lerchbaum’s study 
were performed with varying patient groups in the mean of body 
mass indeces and usually homeostasis model assessment of 
insulin resistance (HOMA-IR) was used instead of  “gold standard 
method”  hyperinsulinemic euglycemic clamp (HEC) to evaluate 
insulin resistance.
In the present study, we aimed to observe the controversial 
presence of insulin resistance in lean PCOS subjects with HOMA-IR 
and HEC, and also to assess the impacts of family history of T2DM 
on insulin resistance. Especially non-obese PCOS patients were 
recruited to our study for excluding the aggravation of insulin 
resistance caused by excess fat tissue.
Materials and Methods
Selection of Participants
This study was performed with subjects who referred to Başkent 
University Endocrinology and Metabolism Diseases Outpatient 
Clinic and it was designed as a prospective case control study. PCOS 
patients were diagnosed according to the Rotterdam revised 2003 
consensus on diagnostic criteria (12). Patients had to have at least 
two of the following conditions; 1) oligo- and/or anovulation, 2) clinical 
and/or biochemical signs of hyperandrogenism, 3) polycystic ovaries 
and exclusion of other aetiologies (congenital adrenal hyperplasias, 
androgen-secreting tumours, Cushing’s syndrome) (12). Chronic 
ovulatory dysfunction was defined as intermenstrual intervals of ≥45 
days or a total of fewer than eight menses per year (13).
Exclusion criteria for the study were; 1) a prior diagnosis of type 
1 or type 2 diabetes mellitus, 2) overweight and obese subjects 
whose BMI were ≥25 (14), 3) pregnancy, 4) hysterectomy 
and/or oophorectomy history, 5) thyroid dysfunction, 6) 
hyperprolactinemia, 7) patients using drugs which affect 
glucose metabolism and insulin sensitivity like metformin or 
thiazolidinediones, 8) patients using drugs which may affect 
reproductive or metabolic functions like oral contraceptives, 
steroids, beta blockers, anti-androgen drugs, 9) known significant 
cardiovascular disease, 10) cancer history and 11) evidence of any 
unresolved medical problem. 
Patients were divided into two groups according to their FH of 
T2DM among their first degree relatives; FH positive (FHpos) versus 
FH negative (FHneg). Standard (75 grams) oral glucose tolerance 
test (OGTT) was performed on FHneg patients’ first degree relatives 
to exclude the possibility of unknown T2DM. Age and body mass 
index (BMI) matched control group was composed of healthy 
women who had regular menstrual cycles and who were free of 
any clinical signs of hyperandrogenism. All of the control subjects 
also did not have a positive FH of T2DM among their first degree 
relatives.  
This study was approved by Başkent University Institutional Review 
Board and Ethics Committee with project number KA 06/269 
and supported by Başkent University Research Fund. A written 
informed consent was provided from all patients and controls at 
inclusion.
Methods
Weight and height of the patients and controls were measured 
with a standard steelyard in the morning after 12 hours of 
fasting. Body mass index (BMI) was calculated as kg/m2. Waist 
circumference (WC) was measured at the midpoint between the 
iliac crest and lower rib margin. All of the subjects were examined 
for the clinical evidence of hyperandrogenism such as acne, 
androgenic alopecia, acanthosis nigricans, striae, clitoromegaly 
and increased muscle mass. The degree of hirsutism was 
assessed using the modified Ferriman Gallwey (mFG) score in the 
upper lip, chin, areola and chest, upper back, lower back, upper 
abdomen, lower abdomen, thighs, and upper arms. Hirsutism 
was classified as mild (score 8-16), moderate (score 17-24), and 
severe (score >24). Transabdominal ultrasonography (USG) was 
performed during the early follicular phase of menstrual cycle. 
The USG criteria to define polycystic ovaries were presence 
of 12 or more follicles in each ovary measuring 2 to 9 mm in 
diameter, and/or increase in ovarian volume (>10 mL) and only 
one ovary fitting this definition is sufficient for diagnosis (12). All the 
measurements and physical examinations were performed by the 
same researcher. A diet containing 300 grams of carbohydrates 
was given to all subjects for three days before insulin resistance 
assessments. All of the laboratory tests and HEC were performed 
after 10-14 hours of fasting. Blood samples were obtained from 
the forearm brachial veins during the early follicular phase of 
menstrual cycle. HOMA-IR index was calculated by using the 
formula; fasting insulin concentration (μIU/mL) x fasting glucose 
(mg/dL)/405, assuming that normal adults have a score <2.5 
(15). Blood glucose was determined with enzymatic colorimetric 
assay (glucose oxidase) by using Roche Modular Biochemistry 
Analyzer (Roche Diagnostics, Mannheim, Germany). Insulin levels 
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were studied with microparticle enzyme immunoassay by using 
Axsym Analyzer (Abbott Diagnostics Division, Illinois, USA). HEC 
was performed in the morning (starting between 08:00-10:00 
AM) as described by DeFronzo et al. (16). M value, which has 
been described as the glucose amount required to maintain 
euglycemia under steady dose of insulin infusion was calculated. 
Prolactin and thyroid stimulating hormone (TSH) were assessed 
in all participants including control subjects by chemiluminescent 
microparticle immunoassay (CMIA) with Architect Analyzer (Abbott 
Diagnostics Division, Illinois, USA) to exclude asymptomatic 
hyperprolactinemia and thyroid dysfunction. Also; follicle 
stimulating hormone (FSH), luteinizing hormone (LH) and estradiol 
were studied with CMIA by using Architect Analyzer (Abbott 
Diagnostics Division, Illinois, USA), free testosterone (fT) and 17 
alpha hydroxyprogesterone (17αOHP) leves were evaluated 
with enzyme immunoassay by using Tecan Sunrise Analyzer 
(BLK Diagnostics, Badalona, Spain), dehydroepiandrosterone 
sulfate (DHEAS) was determined with solid phase competitive 
chemiluminescent enzyme immunoassay by using Immulite 2000 
Analyzer (Corporate Offices, Los Angeles, USA) just for patients 
with PCOS.
Statistical Analysis
Statistical analysis was performed by using SPSS software (Version 
17.0, SPSS Inc., Chicago, IL, USA). An assessment of the normality 
was done initially. All the normally distributed numerical data 
were expressed as mean values ± standard deviation (SD), while 
non-normally distributed data were expressed as median with 
minimum (min) and maximum (max) values. Nonparametric 
tests were used because of the limited number of patients in 
the groups.  Comparisons between quantitative data were 
determined with Mann-Whitney U test, while  comparisons 
between qualitative data were studied by using Chi-square 
test. Independent factors affecting HOMA-IR and M values were 
assessed with Kruscall Wallis correlation coefficient. Spearmans 
correlation coefficient  was used to evaluate the correlation 
between HOMA-IR and M values. Correlation coefficients were 
interpreted as either excellent relationship r≥0.91; good 0.90≤ r 
≥0.71; fair 0.970≤ r ≥0.51; weak 0.50≤ r ≥0.31; little or none r ≤0.3. 
The level for statistical significance was considered as p<0.05. 
However, while interpreting the difference among three groups 
Mann-Whitney U test was used to compare groups two-by-two 
and Bonferroni correction was performed. The level for statistical 
significance was considered as p<0.017 for these evaluations.
Results
Total of 19 PCOS patients as study group and 9 healthy subjects 
as a control group were enrolled to the study. Nine patients with 
PCOS had FH of T2DM among one of their first degree relatives 
and called as FHpos group, while 10 PCOS patients didn’t have 
any T2DM history among their first degree relatives and called as 
FHneg group. General characteristics of patients with PCOS and 
control subjects are summarized in Table 1. In the FHpos group; 
six patients’ mother, two patients’ father and only one patient’s 
both of parents were diabetic. This patient’s HOMA-IR and M 
values were calculated as 3.37 and 4.85 respectively in a manner 
of exhibiting evident insulin resistance. All of the findings were 
similar when patients with PCOS were compared with control 
subjects except for M values. M values were significantly higher 
in the control group (p=0.003) (Table 1).
Early follicular phase hormone profiles of FHneg and FHpos 
groups were compared and no statistically significant difference 
was found (Table 2). Also there was no statistically significant 
difference in the means of mFG hirsutism scores, menstruation 
cycles, ovulation status, existence of hyperandrogenism signs 
and pelvic USG findings between these groups. After that, FHneg 
and FHpos groups were compared with controls individually. 
Results are summarized in Table 3. Although HOMA-IR values 
were similar between groups, M values were lower in FHneg 
and FHpos groups compared to the controls (p=0.02 and 0.004 
respectively).Variance analysis within all PCOS patients revealed 
Table 1. General characteristics of  patients with Polycystic ovary 
syndrome and control subjects
Patients with PCOS 
(n=19)
Controls 
(n=9)
p
Age (years) 22.68±3.07 22.78±2.11 NS
Height (cm) 161±5.64 162.22±3.15 NS
Weight (kg) 59.79±8.05 60.11±2.89 NS
BMI (kg/m2) 23.06±2.71 22.85±1.12 NS
Waist circumference 
(cm)
75.05±7.25 75.56±1.12 NS
Fasting glucose 
(mg/dL)
86.74±7.67 85.22±5.02 NS
Fasting insulin 
(μIU/mL)
8.00 (4.50-22.50) 6.70 (3.80-14.90) NS
HOMA-IR 1.91 (0.91-4.44) 1.59 (0.37-3.58) NS
M value 5.32 (4.44-10.60) 8.24 (6.10-12.92) 0.003
Normally distributed data are presented as the mean ± SD. Non-normally 
distributed data are presented with median and minimum-maximum (min-max) 
values. NS: not significant PCOS: Polycystic ovary syndrome BMI: Body mass index
Table 2. Comparison between FHneg and FHpos groups
FHneg group 
(n=10)
FHpos group 
(n=9)
P
mFG Hirsutism score 16.00±2.36 13.44±3.81 NS
FSH (mIU/mL) 4.82±1.14 4.98±1.21 NS
LH (mIU/mL) 4.14 (2.36-17.90) 6.60 (2.47-10.36) NS
Estradiol (pg/mL) 36.50 (23-76) 40.00 (18-60) NS
Free Testosterone (pg/mL) 1.98 (0.86-4.50) 2.59 (1.80-8.40) NS
TSH (μIU/mL) 1.03 (0.56-3.60) 1.90 (0.65-2.50) NS
Prolactin (mIU/L) 284 (145-560) 423 (163-884) NS
17αOHP (ng/mL) 0.80 (0.50-1.60) 1.04 (0.78-1.43) NS
DHEAS (ng/mL) 2210 (344-3570) 2580 (1922-4350) NS
Normally distributed data are presented as the mean ± SD. Non-normally 
distributed data are presented with median and minimum-maximum (min-max) 
values. NS: not significant
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that none of the examined factors affected HOMA-IR and M 
values independently. 
Discussion
Hyperinsulinemia and insulin resistance are well known features 
of PCOS. In the literature, it is shown that 50-60% of patients 
with PCOS have insulin resistance (17,18). Obese patients with 
PCOS have decreased insulin sensitivity when compared to 
normal-weight PCOS patients and obese patients without PCOS 
(19,20). However, insulin resistance in lean PCOS subjects is still 
a controversial issue. When we searched the literature assuming 
that the gold standard method to assess insulin resistance is 
HEC; we found two relatively big studies with conflicting results. 
Vrbikova et al. reported similar findings between normal-weight 
patients and control subjects, while Li et al. reported increased 
insulin resistance in Chinese normal-weight PCOS women 
compared to controls (6,21).  In a manner of supporting findings 
of the latter study; we found significantly increased insulin 
resistance in lean PCOS patients in our study (Table 1). Although 
HOMA-IR values of PCOS patients and control subjects were 
similar, there was statistically significant difference among M 
values. This issue can be explained by the limited number of 
subjects. When compared to HOMA-IR; HEC is more sensitive 
and specific, but its application is much more difficult. HOMA-IR 
assessment is very practical but its sensitivity and specificity is 
very low in studies with small patient groups, and it seems to 
be suitable for relatively larger studies (22). Additionally, another 
reason explaining this issue may be the effect of postprandial 
hyperinsulinemia. Usually postprandial hyperinsulinemia may 
be onset before fasting hyperinsulinemia, and can be more 
important in IR (23). HOMA-IR is a predictor of insulin response 
to fasting glucose, however HEC test predicts both fasting and 
postprandial glucose/insulin response.
In the normal population, offsprings with one diabetic parent have 
1.6-2.6 times increased risk for diabetes, while this ratio increases 
to 2.2-3.7 in subjects with two diabetic parents (24). There is 
no remarkable difference between maternal and paternal 
inheritance (24). In addition, literature also reveals pancreas 
β-cell dysfunction and increment in insulin resistance among 
first degree relatives of PCOS patients (8,25). In another study, 
Ehrmann et al. reported a close relation between T2DM FH and 
increased insulin resistance in obese PCOS patients (9). However 
there are limited and conflicting data concerning T2DM FH among 
lean PCOS patients. 
In our study, we didn’t find any statistically significant difference 
regarding insulin resistance between T2DM FHneg and FHpos 
patient groups. However both of the patient groups showed 
increased insulin resistance when compared with the control 
subjects. This finding was shown with M values assessed by 
HEC technique. Additionally this difference was more prominent 
in the FHpos group (p=0.02 for FHneg group versus p=0.004 
for FHpos group). Probably depending on the limited number of 
patients this issue was not confirmed with HOMA-IR evaluations. 
The difference between FHpos and FHneg patients in the mean of 
insulin resistance might become more evident with a larger study 
group. For this reason our study results are not adequate to say 
that FH of T2DM does not have any impact on insulin resistance in 
lean PCOS subjects. On the other hand we can say that we didn’t 
observe any apparent impact of  T2DM FH on insulin resistance 
in our study group.
Limitations of this study were; (1) limited number of patients, (2) 
hormones other than TSH, prolactin and insulin were not studied 
for control subjects. Small number of participants was due to the 
difficulty of HEC technique and finding non-obese PCOS patients. 
Secondly, we didn’t assess many hormones in the control group 
because of the cost. However these hormones are not essential 
to rule out PCOS diagnosis according to Rotterdam revised 2003 
diagnostic criteria (12).
As a conclusion, our study results suggest that lean PCOS 
patients have evident insulin resistance when compared to 
healthy subjects. After diagnosis, even lean PCOS patients should 
be encouraged to apply healthy life style changes like healthy 
eating style and exercise to prevent future metabolic disorders. 
Furthermore, lean PCOS patients having fertility problems and 
irregular menstrual cycles can see benefits from drugs which 
improve insulin resistance mainly like metformin. According to 
our findings FH of T2DM seems to not affect insulin resistance in 
non-obese PCOS women, but studies with larger study groups 
are required to clarify this issue. Concerning the difficulty of HEC 
technique, multicentric studies can be planned or data derived 
from meta-analysis may be more decisive.
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